Mineralys Therapeutics (MLYS) Share-based Compensation (2022 - 2026)

Mineralys Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $6.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 79.64% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (up 73.78% YoY) and the FY2025 annual result came in at $19.3 million, up 70.47% from the prior year.
• Share-based Compensation grew to $6.5 million in Q1 2026 per MLYS's latest filing, from $5.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.5 million in Q1 2026 and troughed at $19000.0 in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation jumped 4807.69% in 2023, then surged 58.53% in 2025.
• Over 5 years, Share-based Compensation stood at $218000.0 in 2022, then soared by 568.35% to $1.5 million in 2023, then jumped by 115.1% to $3.1 million in 2024, then soared by 68.63% to $5.3 million in 2025, then grew by 23.9% to $6.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $6.5 million, $5.3 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.